Royal Bank of Canada
VIR icon

Royal Bank of Canada’s Vir Biotechnology VIR Stock Holding History

Royal Bank of Canada’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$138K Buy
15,355
+10,603
+223% +$84.5K ﹤0.01% 4943
2025
Q4 		$29K Sell
4,752
-711,636
-99% -$4.24M ﹤0.01% 5852
2025
Q3 		$4.09M Buy
716,388
+9,162
+1% +$46.8K ﹤0.01% 2831
2025
Q2 		$3.56M Buy
707,226
+683,864
+2,927% +$3.67M ﹤0.01% 2851
2025
Q1 		$152K Buy
23,362
+7,476
+47% +$66.5K ﹤0.01% 4909
2024
Q4 		$117K Buy
15,886
+3,435
+28% +$27.1K ﹤0.01% 5238
2024
Q3 		$94K Buy
12,451
+2,036
+20% +$17.7K ﹤0.01% 5387
2024
Q2 		$93K Buy
10,415
+4,946
+90% +$47.4K ﹤0.01% 5310
2024
Q1 		$55K Sell
5,469
-22,630
-81% -$230K ﹤0.01% 5503
2023
Q4 		$283K Buy
28,099
+9,842
+54% +$89.9K ﹤0.01% 4788
2023
Q3 		$171K Buy
18,257
+5,579
+44% +$79.6K ﹤0.01% 4949
2023
Q2 		$311K Buy
12,678
+3,713
+41% +$93.2K ﹤0.01% 4355
2023
Q1 		$208K Sell
8,965
-5,233
-37% -$134K ﹤0.01% 4599
2022
Q4 		$360K Buy
14,198
+10,073
+244% +$247K ﹤0.01% 4400
2022
Q3 		$79K Buy
4,125
+510
+14% +$13K ﹤0.01% 5470
2022
Q2 		$92K Sell
3,615
-9,638
-73% -$225K ﹤0.01% 5391
2022
Q1 		$341K Sell
13,253
-725
-5% -$21.5K ﹤0.01% 4612
2021
Q4 		$585K Buy
13,978
+13,728
+5,491% +$538K ﹤0.01% 4328
2021
Q3 		$11K Hold
250
– – ﹤0.01% 6940
2021
Q2 		$12K Sell
250
-2,118
-89% -$96.3K ﹤0.01% 6812
2021
Q1 		$121K Buy
2,368
+2,213
+1,428% +$119K ﹤0.01% 5329
2020
Q4 		$4K Sell
155
-21
-12% -$683 ﹤0.01% 6751
2020
Q3 		$6K Sell
176
-74
-30% -$3.19K ﹤0.01% 6101
2020
Q2 		$10K Buy
250
+34
+16% +$1.14K ﹤0.01% 5838
2020
Q1 		$7K Sell
216
-287
-57% -$7.71K ﹤0.01% 5952
2019
Q4 		$6K Buy
+503
New +$6.74K ﹤0.01% 6310

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Royal Bank of Canada's VIR Position: Q1 2026 in Review

Royal Bank of Canada increased its Vir Biotechnology (VIR) stake by 223% in Q1 2026, buying an estimated $84.5K and bringing the position to 15,355 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #4943.

Royal Bank of Canada first reported a position in VIR in Q4 2019 and has held it in 26 quarters since. The position peaked at $4.09M in Q3 2025. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Royal Bank of Canada held 15,355 shares of Vir Biotechnology worth $138K as of Q1 2026.
  • Royal Bank of Canada bought 10,603 Vir Biotechnology shares in Q1 2026, an estimated $84.5K.
  • Vir Biotechnology made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4943 holding.
  • Royal Bank of Canada first reported a position in Vir Biotechnology in Q4 2019 and has held it in 26 quarters since.
  • Royal Bank of Canada's Vir Biotechnology position peaked at $4.09M in Q3 2025.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.